Randomized, Double-Blind, Placebo-Controlled Study of Divalproex Extended Release Loading Monotherapy in Ambulatory Bipolar Spectrum Disorder Patients With Moderate-to-Severe Hypomania or Mild Mania
Objective: To determine whether divalproex extended release (ER) would be effective in outpatients with DSM-IV-TR–diagnosed ambulatory bipolar spectrum disorder (BSD) and moderate-to-severe hypomanic or mild manic symptoms (hypomania/mild mania).
Method: An 8-week, randomized, double-blind, placebo-controlled trial of divalproex ER oral loading (begun at 15 mg/kg/d and titrated to a maximum of 30 mg/kg/d) in ambulatory BSD with hypomania/mild mania patients, operationally defined as a Young Mania Rating Scale (YMRS) score ≥ 10 but < 21 at baseline and at 1 other study visit at least 3 days apart over the 2 weeks before baseline, was conducted. Patients were enrolled from October 2003 through November 2007.
Results: Sixty patients (n = 30 in the divalproex ER group) had at least 1 postbaseline assessment. The divalproex ER group showed a significantly greater rate of reduction in mean total YMRS score than the placebo group (longitudinal analysis, P = .024). The divalproex ER group also showed more improvement in depressive symptoms the greater the severity of baseline depression (P = .11 for analysis of covariance treatment-by-baseline interaction). Baseline-to-endpoint change scores using last-observation-carried-forward showed that divalproex ER was associated with a marginally significant change in mean total YMRS score (P = .080). Comparable numbers of patients discontinued divalproex ER (n = 17) and placebo (n = 15), including those that discontinued use because of adverse events (n = 4 and 3, respectively).
Conclusions: Divalproex ER begun at 15 mg/kg/d was superior to placebo in reducing hypomanic/mild manic symptoms in ambulatory BSD. It was associated with fairly good tolerability but a high discontinuation rate. Controlled trials of divalproex ER and other mood stabilizers in larger groups of ambulatory BSD patients with hypomanic/mild manic symptoms appear warranted.
Trial Registration: clinicaltrials.gov Identifier: NCT00278772
J Clin Psychiatry 2010;71(5):557–565
© Copyright 2010 Physicians Postgraduate Press, Inc.
Submitted: November 5, 2008; accepted January 9, 2009.
Online ahead of print: February 23, 2010 (doi:10.4088/JCP.08m04854yel).
Corresponding author: Susan L. McElroy, MD, 4075 Old Western Row Road, Mason, OH 45040 (email@example.com).
Bipolar spectrum disorder (BSD) is more common than previously realized, due in part to increased recognition of cases with hypomanic and subthreshold hypomanic/manic symptoms.1–7 For example, in the National Comorbidity Survey Replication (NCS-R), which found a total lifetime prevalence of BSD of 4.4%, the lifetime prevalences of bipolar I and II disorders were 1.0% and 1.1%, respectively, while the lifetime prevalence for subthreshold BSD was 2.4%.7 The latter was defined as a recurrent hypomania without a major depressive episode or with fewer symptoms than required for threshold hypomania.
These findings suggest that some BSD patients who require mood stabilizers will have such agents begun when they have hypomanic or mild manic symptoms in outpatient settings. However, the majority of randomized, placebo-controlled pharmacotherapy studies in acutely symptomatic BSD patients with manic symptoms have been done, at least initially, in hospitalized patients with bipolar I manic or mixed episodes.8–10 Very few randomized, placebo-controlled studies have been conducted exclusively in BSD outpatients with hypomania or mild mania.11–14 The lack of such trials makes it less clear how to treat ambulatory BSD with hypomanic/ mild manic symptoms. Indeed, treatment guidelines for hypomania and mild mania in outpatients are largely generalized from the studies of moderate-to-severe mania conducted in inpatients,8,15–17 sometimes modified with data from open-label reports in outpatients.18
Patients with ambulatory BSD may be more likely to present to general medical than to psychiatric practice settings, where they are more likely to receive antidepressants than mood stabilizers.6,7,19 The NCS-R study found that although most people with BSD received lifetime professional treatment for emotional problems, use of antimanic medications was uncommon, especially in general medical settings.6 The lack of empirically based treatment guidelines regarding initiation of mood stabilizers in ambulatory BSD patients with hypomanic/mild manic symptoms, along with the likelihood that many ambulatory BSD patients are treated in general medical practice settings, suggests the need for controlled trials of mood stabilizers in this population.20
Like its parent compound divalproex delayed release (DR), divalproex extended release (ER) is approved for treatment of acute manic and mixed episodes associated with bipolar I disorder.21,22 Because of its documented efficacy in bipolar I manic and mixed episodes, along with its favorable tolerability profile and convenient once-daily dosing, we hypothesized that divalproex ER would be effective for ambulatory BSD with moderate-to-severe hypomanic or mild manic symptoms, including when accompanied by mild-to-marked depressive symptoms (eg, mixed hypomania and mixed mild mania).22–24 In light of reports of divalproex DR,25–28 and more recently divalproex ER,21,29 being successfully orally loaded in patients with acute bipolar mania (usually at doses of 20–30 mg/kg/d), we also hypothesized that divalproex ER could be initiated in ambulatory BSD patients with hypomanic/mild manic symptoms via a similar oral loading strategy, with subsequent dosing adjusted according to clinical response and tolerability. However, because we were concerned that such patients might not tolerate the same initial dosage regimens that hospitalized acutely manic patients have tolerated, we thought it prudent to choose a lower loading dose (15 mg/kg/d rather than 25–30 mg/kg/d) and to give the medication at bedtime (rather than in the morning).21,29 Indeed, there are reports of patients with bipolar II and cyclothymic disorders responding to lower valproate doses (ie, 125–500 mg/d) and serum levels (ie, mean = 32.5 µg/mL) than are generally required for patients with bipolar I disorder.30
We, therefore, conducted a single-center, randomized, parallel-group, double-blind, placebo-controlled clinical trial to assess the efficacy and tolerability of divalproex ER loading monotherapy in BSD outpatients with moderate-to-severe hypomania or mild mania. Divalproex ER was begun at 15 mg/kg/d given at bedtime and adjusted according to response and side effects to a maximum dose of 30 mg/kg/d. Moderate-to-severe hypomania and mild mania were operationally defined as a Young Mania Rating Scale (YMRS)31 score ≥ 10 and < 21 on 2 separate days, 3 or more days apart, and within the 2-week period prior to randomization.
Study participants were outpatients at the University of Cincinnati Medical Center who were recruited by radio, newspaper, and television advertisements requesting volunteers for a study of a medication for persons with bipolar disorder who had manic symptoms. Patients were enrolled into the trial if they met the following inclusion criteria: (1) were male or female 18 years of age or older; (2) met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)32 criteria for bipolar I or II disorder or bipolar disorder not otherwise specified and who were currently experiencing a hypomanic, manic, or mixed episode (as determined by the Structured Clinical Interview for DSM-IV-TR33); (3) had moderate-to-severe hypomania or mild mania within the past 2 weeks, operationally defined as having a YMRS score ≥ 10 and < 21 at the baseline assessment and at least 1 prior study screening visit at least 3 days, but no longer than 2 weeks, before baseline; (4) had an overall Clinical Global Impressions-Bipolar Version (CGI-BP) scale34 score ≥ 2 and < 5; (5) were outpatients (ie, were ambulatory and did not require hospitalization for management of their bipolar symptoms); and (6) were receiving no psychotropics for the 1 week (4 weeks for fluoxetine or depot antipsychotics) before the baseline assessment, except as needed lorazepam (up to 2 mg/d) or zaleplon (up to 10 mg/d).
Patients were excluded from study participation if they met any of the following criteria: (1) were considered severely psychiatrically ill or in need of psychiatric hospitalization in the judgment of the clinical investigator; (2) had a baseline YMRS score ≥ 21, CGI-BP score ≥ 5, or Inventory of Depressive Symptoms (IDS)35 score ≥ 39; (3) were experiencing clinically significant suicidal ideation, homicidal ideation, or psychotic features; (4) had a current DSM-IV-TR diagnosis of delirium, dementia, or other cognitive disorder or a lifetime DSM-IV-TR psychotic disorder; (5) had a DSM-IV-TR substance dependence disorder (except for nicotine dependence) within 3 months of study entry, a current DSM-IV-TR diagnosis of cocaine, stimulant, or hallucinogen abuse, or a urine drug screen positive for cocaine, stimulants, or hallucinogens; (6) had a clinically significant finding on medical history, physical examination, electrocardiogram, or laboratory testing; and (7) had a history of allergy or hypersensitivity to any valproate or divalproex preparation. Women were excluded if they were pregnant, lactating, or, if fertile, not practicing a form of medically accepted contraception.
The institutional review board at the University of Cincinnati Medical Center approved the study protocol, and the study was conducted in compliance with the Declaration of Helsinki. All patients signed approved written informed consent forms after the study procedures had been fully explained and before any study procedures were performed. Patients were enrolled from October 2003 through November 2007.
This was an 8-week, outpatient, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose study conducted at the University of Cincinnati Medical Center. The trial consisted of 2 phases: a 1- to 2-week screening period and an 8-week double-blind treatment period. Patients were evaluated at least twice during the screening period and after 1, 2, 3, 4, 6, and 8 weeks during the treatment period. They were also evaluated on at least one occasion 1 week after study medication discontinuation.
All study medication was in identical 500-mg tablets supplied in numbered containers and dispensed to patients according to a predetermined randomization schedule. Divalproex ER was administered at an initial dose of 15 mg/kg/d, rounded up or down to the nearest 500 mg, and subsequently adjusted to a dose considered optimal based on the patient’s clinical response and side effects, but not to exceed 30 mg/kg/d. As needed (prn) use of lorazepam 0.5–2.0 mg/d was allowed for the management of affective symptoms for the first 2 weeks of the study; prn lorazepam 0.5–1.0 mg/d was allowed for the next 2 weeks. No lorazepam was permitted for the final 4 weeks. As needed zaleplon (10–20 mg/d at bedtime) was allowed for management of insomnia throughout the study.
Patients were randomly assigned to receive divalproex ER or placebo in a 1:1 ratio according to computer-generated coding. Randomization was balanced by use of permuted blocks. Allocation concealment was achieved by having the research pharmacy perform the randomization, package the study medication, and maintain the integrity of the blinded information throughout the trial.
The primary outcome measure was change in hypomanic/mild manic symptoms as assessed by the YMRS.31 The YMRS is an extensively validated 11-item health care professional–administered test that has been in use since 1978. Secondary measures were the IDS,35 the CGI-BP scale,34 the Hamilton Anxiety Rating Scale (HARS),36 and the Global Assessment of Functioning (GAF) scale.32 Response was defined as a 50% or greater decrease in baseline YMRS score at treatment endpoint.
The following safety measures were assessed: adverse events, clinical laboratory data, physical examination findings, and vital signs. Hematology parameters, liver function tests, and blood chemistries were collected at screening and weeks 1, 2, 4, and 8 (or at discontinuation). A physical examination and urinalysis were performed at screening and week 8 (or at discontinuation). Serum valproate levels, generally drawn 12–18 hours after study drug was taken, were obtained after 1, 2, 4, and 8 weeks of treatment (or at discontinuation) and monitored by blinded investigators (A.I.G., P.E.K.). Unblinded investigators were to be notified only of concentrations ≥ 150 µg/mL. To maintain the blind, similar notifications were to be given for a placebo patient who was at the same point in the study. No serum valproate levels, however, exceeded 150 µg/mL.
Adherence with study medication was evaluated with returned capsule count. Patients who missed ≥ 5 consecutive days of study medication were considered nonadherent and discontinued from the trial.
The baseline characteristics of each treatment group were compared using the Fisher exact test for categorical variables and independent samples t tests for continuous variables.
Two efficacy analyses were used to compare change between the groups over the treatment period. These were applied to scores on the YMRS total score (the primary efficacy measure) as well as the IDS, CGI-BP (severity of mania, depression, and overall bipolar disorder), HARS, and GAF scales (secondary efficacy measures). The difference in rate of change was estimated by random regression methods for longitudinal data, as described in Fitzmaurice et al37 and Gibbons et al,38 and by a comparison of baseline-to-endpoint change scores (with the last available observation substituted for the week-8 observation for patients who discontinued the trial early). These analyses differ in the assumptions they make about the data that would have been observed following dropout for patients who failed to complete the trial. The regression analysis carries the assumption that the linear trend observed for each patient up to the point of dropout would have continued until the end of the trial. The analysis of change scores, by substituting the last available observation, assumes that scores would remain constant following dropout (ie, the last observation is implicitly carried forward and used as an estimate for the week-8 observation). Since both scenarios are plausible and neither can be empirically verified, we did not designate 1 model as the preferred analysis. Rather, we considered similar results as evidence of robustness against the influence of sample attrition.
For the longitudinal regression models, a model for the mean of the outcome variable that included terms for treatment, time, and treatment-by-time interaction was used. Time was modeled as a continuous variable, expressed as the square root of days since randomization (baseline). To simultaneously account for individual differences in initial level of the outcome, rate of change over time, and serial autocorrelation, we used the SAS version 9.1 procedure MIXED (SAS Institute, Inc, Cary, North Carolina) with random intercept and slope terms and a first-order antedependence structure for the residual correlation matrix. The longitudinal analyses were intent-to-treat, using all available observations from all time-points from all patients who completed a baseline evaluation.
The Fisher exact test was used to analyze categorical response to treatment and rates of adverse events. All statistical tests and confidence intervals were 2-sided, α = .05.
Click figure to enlarge
Of 150 individuals assessed for eligibility, 88 were not enrolled because they chose not to participate (n = 19) or did not meet entry criteria (n = 69) (Figure 1). Sixty-two patients who met entry criteria were randomly assigned to divalproex ER (n = 31) or placebo (n = 31). Sixty patients (n = 30 receiving divalproex ER and n = 30 receiving placebo) had at least 1 postrandomization efficacy measure. Thirty-six patients (60%) were women, 48 (80%) were white, and 10 (17%) were African American. Forty-four patients (73%) were hypomanic and 16 (27%) were mildly manic; 33 (55%) were mixed, which was defined as meeting DSM-IV-TR criteria for a major depressive episode and hypomania (n = 24) or mania (n = 9) within the month prior to baseline. There were no significant differences between the treatment groups in demographic or clinical variables at baseline, though there was a trend for the divalproex ER group to have more patients with mixed hypomania (Table 1).
Seventeen patients (57%) in the divalproex ER group and 15 patients (50%) in the placebo group did not complete all 8 weeks of treatment (Fisher exact test, P = .796). Seven patients withdrew from the study because of adverse events, 11 withdrew because of lack of efficacy, 4 withdrew for administrative reasons, and 10 were lost to follow-up (Table 2). The remaining 28 patients (47%) completed the 8 weeks of treatment (n = 13 receiving divalproex ER and n = 15 receiving placebo).
Click figure to enlarge
The efficacy analysis using random regression showed that patients receiving divalproex ER had a significantly greater rate of reduction in mean total YMRS score than patients receiving placebo (Table 3; Figure 2 ). They also had significantly greater rates of reduction in CGI-BP mania and CGI-BP overall scores. The associated standardized effect sizes were moderate (Cohen d = 0.59, 0.53, and 0.52, respectively). There were no differences in the rates of change in the IDS, CGI-BP depression, HARS, or GAF scores. However, change in IDS score as a function of baseline IDS score showed a trend wherein, compared with the placebo group, the divalproex ER group showed more improvement in depression the greater the severity of baseline depression (P = .11 for analysis of covariance treatment-by-baseline interaction) (Figure 3).
Click figure to enlarge
In the efficacy analysis of baseline-to-endpoint change scores using last-observation-carried-forward, divalproex ER was associated with a marginally significant change for the mean total YMRS score but not with any of the secondary outcome variables (Table 3). There were no significant differences between treatment groups for any global or categorical response analyses (all intent-to-treat), though response rates in the divalproex ER groups were numerically greater than response rates in the placebo groups in each category (Table 4).
The mean (SD) daily dose of divalproex ER at endpoint evaluation for the 27 patients with available data was 2,204 (524) mg (range, 1,500–3,000). The mean (SD) serum valproate concentration for this group was 68.1 (45.7) μg/mL. The mean (SD) number of hours at which these levels were drawn after the last divalproex ER dose was 14.9 (7.8) hours (range, 2–35). The mean (SD) daily dose for the 12 patients who completed the 8-week trial was 2,091 (437) mg. The mean (SD) serum valproate concentration for this group was 55.4 (45.5) µg/mL. The mean (SD) number of hours at which the levels were drawn after the last divalproex ER dose was 11.2 (6.2) hours (range, 2-19).
Click figure to enlarge
The groups were comparable with respect to percentages of patients administered lorazepam (n = 1 [3.3%] for divalproex ER versus n = 1 [3.3%] for placebo) or zaleplon (n = 3 [10%] for divalproex ER versus n = 3 [10%] for placebo; P > .99 for comparison of usage rates for both concomitant medications).
Click figure to enlarge
Click figure to enlarge
Click figure to enlarge
Click figure to enlarge
Adverse events occurring in at least 2 patients receiving divalproex ER are listed in Table 5. There were no statistically significant differences between treatment groups in the incidence of individual events, although the sample size was too small to detect moderate differences in event rates. A comparable number of patients discontinued divalproex ER (n = 4) and placebo (n = 3) for adverse events. Adverse events causing discontinuation among divalproex ER–treated patients were thrombocytopenia, severe nausea, menstrual irregularity, and rash (1 per patient). Adverse events causing discontinuation in placebo-treated patients were spontaneous pneumothorax, “ocular migraine versus transient ischemic attack,” and blurry vision (1 per patient). Of note, 2 of these latter events (spontaneous pneumothorax and “ocular migraine versus transient ischemic attack”) were considered serious adverse events. No patient receiving divalproex ER experienced a serious adverse event.
The divalproex ER group gained a mean (SD) of 4.2 (5.3) pounds over the course of the trial, versus 1.0 (3.6) pounds for the placebo group (P = .010). There were no other significant changes in physical examination findings or vital signs. The divalproex ER group had a significant mean decrease in platelet count (from 279.62 to 235.59 thousand/µL, versus 259.27 to 256.57 thousand/µL in the placebo group, P < .001) and a significant mean increase in blood urea nitrogen (from 11.37 to 12.81 mg/dL, versus 14.47 to 12.67 mg/dL in the placebo group, P = .005) and red cell distribution width (from 13.43% to 14.09%, versus 13.97% to 13.71% in the placebo group, P = .008). In addition, in the divalproex ER group, alanine transaminase decreased by a significant amount (from 25.64 to 20.46 U/L, versus 19.53 to 20.70 U/L in the placebo group, P = .011), and aspartate transaminase also decreased by a marginally significant amount (from 21.93 to 19.07 U/L, respectively, versus 18.27 to 18.43 U/L, respectively, in the placebo group, P = .052).
In the longitudinal analysis of this randomized, double-blind trial in 60 ambulatory patients with BSD and moderate-to-severe hypomania or mild mania, over one-half (55%) with mixed features, divalproex ER was significantly superior to placebo in reducing hypomanic/mild manic symptoms and overall severity of illness. These findings had moderate effect sizes. In the change from baseline to endpoint analysis using last-observation-carried-forward, divalproex ER was marginally significant in reducing manic symptoms. Taken together, these findings provide preliminary evidence for the efficacy of divalproex ER, initiated via the oral loading dose of 15 mg/kg, in ambulatory BSD with hypomanic/mild manic symptoms, including when associated with mixed features. This finding is consistent with previous studies showing that divalproex is effective in mania and mixed mania when begun in inpatients with bipolar I disorder and suggests it is also efficacious for hypomania and mixed hypomania when started in outpatients with BSD.
In contrast to manic symptoms, neither depressive nor anxious symptoms were significantly improved, inconsistent with recent findings that divalproex may have acute antidepressant and anxiolytic effects in bipolar I depression, bipolar II depression, and mixed bipolar depression.39–41 Although over one-half of the sample (55%) had mixed features, these negative findings may have been due to lack of adequate power to detect an effect. This possibility was supported by the divalproex ER group showing more improvement in depressive symptoms the greater the severity of baseline depression.
Several other limitations of this study should be considered. One is that the attrition rate was high, with 32 patients (53%) withdrawing before study completion. Indeed, this attrition rate is somewhat higher than that seen in acute inpatient mania trials9,21 and renders the results heavily dependent on assumptions regarding missing data. While the longitudinal analysis, unlike the endpoint analysis, allows that the reasons for missing data can depend on observations obtained before withdrawal (eg, a patient who is failing to improve may be more likely to withdraw), it is, nevertheless, vulnerable to factors that are not measured prior to withdrawal. Moreover, the high attrition rate among patients receiving divalproex ER (43%) suggests a high treatment unacceptability rate and is consistent with high rates of mood stabilizer nonadherence in patients with BSD.42,43 This, in turn, underscores the need for novel treatments for bipolar disorder and for further research into treatment acceptability in this patient population.43
Another limitation is that optimal divalproex ER doses and/or serum valproate concentrations may not have been obtained for some patients.21,44 In the pivotal trial of divalproex ER in hospitalized patients with bipolar mania, in which medication was administered once daily in the morning and blood samples for valproate concentrations were obtained approximately 24 hours later prior to the next divalproex ER dose, the mean final dose (on day 21 or at discontinuation) was 3,057 mg/d and the mean serum valproate concentration was 95.9 µg/mL.21 By contrast, in the present study, the mean final dose was 2,204 mg/d and the mean final serum valproate concentration was 68 μg/mL. Moreover, because patients generally took the study drug at night and had blood samples collected 11–16 hours later, the mean level may have been higher (possibly up to 25%) than the trough value.45–47 It is, therefore, possible that higher divalproex ER doses or higher serum valproate levels would have led to a greater degree of response. However, it is also possible that higher doses and/or levels would have led to a greater attrition rate. Additionally, as noted earlier, there are reports of patients with bipolar II and cyclothymic disorders responding to doses and serum levels of valproate lower than those generally required for patients with bipolar I disorder.30 Unfortunately, this study does not resolve the issue of what the optimal initial dosing strategy of divalproex ER specifically, or of mood stabilizers in general, is for ambulatory BSD with hypomanic/mild manic symptoms.
As this is one of the first randomized, placebo-controlled studies of a mood stabilizer given as monotherapy in ambulatory BSD patients with hypomanic/mild manic symptoms, there might have been important ways to improve the design. Inclusion criteria might have been narrowed to generate a more homogenous study population, for example, by excluding patients with bipolar disorder not otherwise specified or using an alternative operational definition of hypomania/mild mania, such as a YMRS score ≥ 12 or 14 but < 22 or 25 (rather than ≥ 10 but < 21). In addition, divalproex ER could have been administered via a different dosing strategy—either beginning with a higher initial loading dose (eg, 20 or 25 mg/kg/d) or given once daily in the morning.21
Conversely, another limitation is that because persons with substance use disorders, severe personality disorders, and unstable medical disorders were excluded, the results may not generalize to ambulatory BSD when it co-occurs with these conditions. Similarly, because this study was not conducted in a primary care population, it is unknown if its results could be generalized to BSD patients treated in such settings.
In summary, in an 8-week trial in ambulatory BSD, divalproex ER initiated via an oral loading strategy of 15 mg/kg/d was found to be superior to placebo in reducing hypomanic/mild manic symptoms. It was also associated with fairly good tolerability but a high treatment discontinuation rate. Controlled trials of divalproex ER and other mood stabilizers in larger groups of ambulatory BSD patients with hypomanic/mild manic symptoms appear warranted.
Drug names: divalproex (Depakote and others), fluoxetine (Prozac and others), lorazepam (Ativan and others), valproate (Depacon and others), zaleplon (Sonata and others).
Author affiliations: Lindner Center of HOPE, Mason (Drs McElroy, Guerdjikova, and Keck and Messrs Martens and Creech); Department of Psychiatry, University of Cincinnati College of Medicine (Drs McElroy, Welge, Jefferson, Guerdjikova, and Keck and Mr Martens); and Department of Psychology, Xavier University, Cincinnati (Mr Creech), Ohio.
Potential conflicts of interest: Dr McElroy is a consultant to or member of the scientific advisory boards of AstraZeneca, Eli Lilly, Jazz, and Schering-Plough; is a principal or co-investigator on research studies sponsored by Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Jazz, National Institute of Mental Health (NIMH), Marriot Foundation, Orexigen, Shire, and Takeda; is inventor on United States Patent No. 6,323,236 B2: Use of Sulfamate Derivatives for Treating Impulse Control Disorders; and has received payments from Johnson & Johnson. Dr Jefferson has received grant/research support from The Program for Minority Research Training in Psychiatry and The American Psychiatric Institute for Research and Education (5T32 MH 19126-18). Dr Keck is presently or has been in the past year a principal or co-investigator on research studies sponsored by AstraZeneca, Cephalon, GlaxoSmithKline, Eli Lilly, Epi-Q, Jazz, Marriot Foundation, NIMH, Orexigen, and Pfizer; has been reimbursed for consulting, in the past year, to GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Quantia MD, Shering-Plough, and Sepracor; and is inventor on United States Patent No. 6,387,956: Methods of Treating Obsessive-Compulsive Spectrum Disorder Comprises the Step of Administering an Effective Amount of Tramadol to an Individual. Drs Welge and Guerdjikova and Messrs Martens and Creech have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.
Funding/support: This investigator-initiated study was funded in part by a grant from Abbott Laboratories. Abbott Laboratories also partially funded poster production costs and the first author’s travel expenses to present the poster.
Previous presentation: This study was presented as a poster at the 161st annual meeting of the American Psychiatric Association on May 5, 2008, in Washington, DC.
1. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50(2–3):143–151. PubMed doi:10.1016/S0165-0327(98)00142-6
2. Akiskal HS, Bourgeois ML, Angst J, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 2000;59(suppl 1):S5–S30. PubMed doi:10.1016/S0165-0327(00)00203-2
3. Angst J, Gamma A, Benazzi F, et al. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar II, minor bipolar disorders and hypomania. J Affect Disord. 2003;73(1–2):133–146. PubMed doi:10.1016/S0165-0327(02)00322-1
4. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73(1–2):123–131. PubMed doi:10.1016/S0165-0327(02)00332-4
5. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003;64(2):53–59. PubMed
6. Das AK, Olfson M, Gameroff MJ, et al. Screening for bipolar disorder in a primary care practice. JAMA. 2005;293(8):956–963. PubMed doi:10.1001/jama.293.8.956
7. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543–552 [Erratum in Arch Gen Psychiatry. 2007; 64:1039]. PubMed doi:10.1001/archpsyc.64.5.543
8. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder (revision). Am J Psychiatry. 2002;159(suppl 4):1–50.
9. Sysko R, Walsh BT. A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry. 2007;68(8):1213–1217. PubMed
10. Talamo A, Baldessarini RJ, Centorrino F. Comparison of mania patients suitable for treatment trials versus clinical treatment. Hum Psychopharmacol. 2008;23(6):447–454. PubMed doi:10.1002/hup.952
11. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000;2(3, pt 2):249–255. PubMed doi:10.1034/j.1399-5618.2000.20305.x
12. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62–69. PubMed doi:10.1001/archpsyc.59.1.62
13. Schaffer A, Levitt AJ. Double-blind, placebo-controlled pilot study of mexiletine for acute mania or hypomania. J Clin Psychopharmacol. 2005;25(5):507–508. PubMed doi:10.1097/01.jcp.0000177852.08287.08
14. Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol. 2007;27(5):498–502. PubMed doi:10.1097/JCP.0b013e31814db4c4
15. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar disorder. J Clin Psychiatry. 2005;66(7):870–886. PubMed
16. Fountoulakis KN, Vieta E, Sanchez-Moreno J, et al. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord. 2005;86(1):1–10. PubMed doi:10.1016/j.jad.2005.01.004
17. Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8(6):721–739. PubMed doi:10.1111/j.1399-5618.2006.00432.x
18. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, pt 2: treatment of mania. 2003. World J Biol Psychiatry. 2003;4(1):5–13. PubMed
19. Hirschfeld RM, Cass AR, Hold DC, et al. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract. 2005;18(4):233–239. PubMed doi:10.3122/jabfm.18.4.233
20. Stang P, Frank C, Yood MU, et al. Bipolar disorder detection, ascertainment, and treatment: primary care physician knowledge, attitudes, and awareness. Prim Care Companion J Clin Psychiatry. 2006;8(3):147–152. PubMed doi:10.4088/PCC.v08n0304
21. Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006;67(10):1501–1510. PubMed
22. Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother. 2007;7(1):9–16. PubMed doi:10.1586/14737220.127.116.11
23. Suppes T, Mintz J, McElroy SL, et al. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. Arch Gen Psychiatry. 2005;62(10):1089–1096. PubMed doi:10.1001/archpsyc.62.10.1089
24. Benazzi F. Delineation of the clinical picture of dysphoric/mixed hypomania. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):944–951. PubMed doi:10.1016/j.pnpbp.2007.02.015
25. Keck PE Jr, McElroy SL, Tugrel KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry. 1993;54(8):305–308. PubMed
26. McElroy SL, Keck PE Jr, Tugrul KC, et al. Valproate as a loading treatment in acute mania. Neuropsychobiology. 1993;27(3):146–149. PubMed doi:10.1159/000118970
27. McElroy SL, Keck PE, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry. 1996;57(4):142–146. PubMed
28. Hirschfeld RM, Baker JD, Wozniak P, et al. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry. 2003;64(7):841–846. PubMed
29. Miller BP, Perry W, Moutier CY, et al. Rapid oral loading of extended release divalproex in patients with acute mania. Gen Hosp Psychiatry. 2005;27(3):218–221. PubMed doi:10.1016/j.genhosppsych.2005.02.001
30. Jacobsen FM. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry. 1993;54(6):229–234. PubMed
31. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978;133:429–435. PubMed doi:10.1192/bjp.133.5.429
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
33. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
34. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159–171. PubMed doi:10.1016/S0165-1781(97)00123-6
35. Rush AJ, Gullion CM, Basco MR, et al. The. Inventory of Depressive Symptoms (IDS): psychometric properties. Psychol Med. 1996;26(3):477–486. PubMed doi:10.1017/S0033291700035558
36. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. PubMed
37. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons; 2004.
38. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry. 1993;50(9):739–750. PubMed
39. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005;85(3):259–266. PubMed doi:10.1016/j.jad.2004.09.009
40. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry. 2007;68(12):1840–1844. PubMed
41. Winsberg ME, DeGolia SG, Strong CM, et al. Divalproex therapy in medication-naïve and mood-stabilizer-naïve bipolar II depression. J Affect Disord. 2001;67(1–3):207–212. PubMed doi:10.1016/S0165-0327(01)00434-7
42. Sajatovic M, Valenstein M, Blow F, et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv. 2007;58(6):855–863. PubMed doi:10.1176/appi.ps.58.6.855
43. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23(2):95–105. PubMed doi:10.1002/hup.908
44. Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry. 2006;163(2):272–275. PubMed doi:10.1176/appi.ajp.163.2.272
45. Dutta S, Reed RC. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Epilepsy Res. 2007;73(3):275–283. PubMed doi:10.1016/j.eplepsyres.2006.11.005
46. Reed RC, Dutta S. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? Ther Drug Monit. 2006;28(3):413–418. PubMed doi:10.1097/01.ftd.0000211814.12311.3f
47. Davis LL, Li X, Bartolucci AA, et al. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex. J Clin Psychiatry. 2007;68(10):1546–1551. PubMed